Medical oncologists rely on nuclear medicine to aid in the detection, diagnosis, staging, and surveillance of several cancers including lung, lymphoma, melanoma, breast, colorectal, esophageal, head and neck, pancreatic, ovarian, cervical, and thyroid cancers. For the majority of tumors, detection is through targeted radionuclides, such as 18FDG, which enables the localization of neoplastic lesions with increased glucose metabolism. Another example is the localization and characterization of neuroendocrine tumors by means of the somatostatin analog octreotide, radiolabeled with Indium-111 (111Inpentetreotide) or, more recently, with the positron emitter Gallium-68 (68Ga-octreotide). For most tumors 18FDG-PET imaging is the most commonly used modality. 18FDG-PET imaging can depict the wholebody distribution of areas of increased metabolic activity, indicating the relative underlying metabolic activity of a tumor. Over 90% of PET utilization is in the field of oncology, with cardiology and neuroscience at a distant 5% and 3%, respectively [24]. As reported by Gambhir et al., 18FDG-PET imaging sensitivity and specificity in oncology are estimated at 84% (based on 18,402 patient studies) and 88% (based on 14,264 patient studies), respectively [25]. It has been shown that adding 18FDG-PET imaging to conventional staging of cancer has altered the management of 13.7-36.5% patients [25]. Currently, exciting applications of PET and SPECT include the indirect visualization of gene expression using reporter probes that aid in the diagnosis as well as monitor the therapeutic treatment of the disease [